Through our core business – the discovery, development and marketing of innovative treatments – we have helped prevent and treat diseases, ease suffering and improve quality of life for people worldwide.

But as the size and complexity of the world’s healthcare challenges grow, we must widen our scope, extending our impact even further by asking: How can we effectively address the needs of underserved populations? How can we bring the benefits of our medicines to more people? And how can we do this in a way that is sustainable for our business?

It begins with a fundamental shift in the way we do business – with reimagining new ways to bridge the divide between those with access to critical healthcare innovations and those without.

We are committed to bringing more of our medicines to more people, no matter where they are. For all our new medicines, we will systematically integrate access strategies in how we research, develop and deliver them globally to reach underserved patients no matter where they live. This will be a key measure of success for our leaders and employees.

Infant patient being held by a healthcare professional during examination

Compassionate use: Providing access to much needed treatments

What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.